Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

KINACEPT

Financiado

Cerrado

Novel anti inflammatory compounds for autoimmune diseases

The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compoun... ver más

30/11/2010

Synovo

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

SYNOVO GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2010-11-30 No tenemos la información de la convocatoria

0% 71% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

Synovo

0.00€ | Lider

RBMF

N.D. | Participante

QMUL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Notid Novel Target for Treatment of Chronic Inflammatory Diseases 3M€ Cerrado

RheumArth New drug for the treatment of rheumatoid arthritis 71K€ Cerrado

MASTERSWITCH Mechanisms to Attack Steering Effectors of Rheumatoid Syndro... 15M€ Cerrado

DESARROLLO PRECLÍNICO NO REGULATORIO DEL PÉPT... DESARROLLO PRECLÍNICO NO REGULATORIO DEL PÉPTIDO MTADV PEMT... 551K€ Cerrado

MOBILISE Monoamine oxidase B inhibitors as novel drugs targeting NLRP... 150K€ Cerrado

PDC2022-133701-I00 INFLAMACION TERAPIAS VIRALES 150K€ Cerrado

Líder del proyecto

SYNOVO GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition, feedback from licensing partners has indicated that clear activity in a range of other disease models would dramatically increase interest. A key issue in bringing substances of this class to the clinic is variable patient response to p38 inhibitors in previous trials. Data to date have indicated that there is a potential groups of responders for whom therapy with this class is highly beneficial. The effect of non-responders has, however, made trial outcomes to variable to warrant further development. To solve this problem, we intend to further extend proof-of-concept in patient stratification to allow us to select responder populations for initial patient trials. The objectives of the project are, therefore: § To prepare analogs of the existing compounds § Conduct pre-clinical models for rheumatoid arthritis, IBD, sepsis, liver fibrosis and motilin dependent gut stimulation § Examine the activity of the compounds in human tissue explant models § Select a pre-clinical candidate class § Develop a scaled-up process for GMP synthesis of the lead § Conduct a survey of p38 expression in IBD and RA sub-types at various stages of disease and correlate this plasma markers. § Based on results of tissue explant studies and p38 expression, select a patient stratification protocol for phase 2A studies in man.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores